Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing Ltd.
ISSN:
1312-773X (Online)
Issue:
2020, vol. 26, issue4
Subject Area:
Medicine
-
DOI:
10.5272/jimab.2020264.3475
Published online: 01 December 2020
Original article

J of IMAB. 2020 Oct-Dec;26(4):3475-3480
IL-18 PROMOTER POLYMORPHISM AND IL-18 SERUM LEVELS IN ASSOCIATION WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
Boncho Grigorov1


, Anastasiya Trenova2
, Antonia Grigorova1
, Spaska Stanilova1
,
1) Department of Molecular Biology, Immunology and Medical Genetics, Medical Faculty Trakia University, Stara Zagora, Bulgaria
2) Department of Neurology, Faculty of Medicine, Medical University of Plovdiv, Bulgaria.
ABSTRACT:
Purpose: Multiple sclerosis is the immune-mediated disorder whose etiology is not completely understood. The present study aimed to survey association between the promoter polymorphism IL18 -607C/A (rs1946518), the serum concentration of IL-18 and susceptibility to relapsing-remitting multiple sclerosis (RRMS) in Bulgarian patients
Material and Methods: This case-control study includes 159 RRMS patients with disease-modifying therapy (DMT) and 162 age-sex-matched healthy volunteers. All included subjects were genotyped by ARMS-PCR while serum levels were measured by enzyme-linked immunosorbent assay (ELISA).
Results: Our results revealed significant differences in the serum levels of IL-18 according to the gender, the onset of disease and the type of disease-modifying therapy. The serum levels of IL-18 are significantly higher in RRMS men compared to RRMS women and the RRMS men with late-onset of the disease (above 30 years) also demonstrated significantly increased serum levels than the women with late-onset of disease and even with healthy men. The RRMS patients treated with interferon-beta showed significantly increased IL-18 serum level than those treated with glatiramer acetate.
Conclusions: Our study shows that the promoter polymorphism IL18 -607C/A is not associated with susceptibility to RRMS in Bulgarian patients as well as the serum level of the cytokine. The observed differences in the serum level of IL-18 in RRMS patients according to gender and the response to therapy could be used as a biomarker to the course of the disease.
Keywords: relapsing-remitting multiple sclerosis, cytokine, rs1946518, SNP,
- Download FULL TEXT /PDF 644 KB/
Please cite this article as: Grigorov B, Trenova A, Grigorova A, Stanilova S. IL-18 promoter polymorphism and IL-18 serum levels in association with relapsing-remitting multiple sclerosis. J of IMAB. 2020 Oct-Dec;26(4):3475-3480. DOI: 10.5272/jimab.2020264.3475
Correspondence to: Boncho Grigorov, PhD, Department of Molecular Biology, Immunology and Medical Genetics, Medical Faculty Trakia University; 11 Armyayska Str., 6000 Stara Zagora, Bulgaria; E-mail: boncho.g@gmail.com
REFERENCES:
1. Berer K, Krishnamoorthy G. Microbial view of central nervous system autoimmunity. FEBS Lett. 2014 Nov 17;588(22):4207-13. [PubMed] [Crossref]
2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008 Oct 25;372(9648):1502-17. [PubMed] [Crossref]
3. Babaloo Z, Aliparasti M, Babaiea F, Almasi S, Baradaran B, Farhoudi M. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels. Immunol Lett. 2015 Apr;164(2):76-80. [PubMed] [Crossref]
4. Arellano G, Ottum PA, Reyes LI, Burgos PI, Naves R. Stage-Specific Role of Interferon-Gamma in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. Front immunol. 2015 Sept 29;6:492. [PubMed] [Crossref]
5. Baker KJ, Houston A, Brint E. IL-1 Family Members in Cancer; Two Sides to Every Story. Front Immunol. 2019 Jun 7;10:1197. [PubMed] [Crossref]
6. Swain SL. Interleukin 18: tipping the balance towards a T helper cell 1 response. J Exp Med. 2001 Aug 6;194(3): F11-4. [PubMed] [Crossref]
7. Yuanyuan G, Xue Y, Yachao L, Xiao F, Xu C. Association between IL-18 -607 C/A Polymorphism and the Risk of Prostate Cancer: A Meta-Analysis of Case-Control Studies. Asian Pac J Cancer Prev. 2019 Jun 1;20(6):1595-1602. [PubMed] [Crossref]
8. Orhan G, Eruyar E, Mungan SO, Ak F, Karahalil B. The association of IL-18 gene promoter polymorphisms and the levels of serum IL-18 on the risk of multiple sclerosis. Clin Neurol neurosurg. 2016 Jul;146:96-101. [PubMed] [Crossref]
9. Taheri M, Hashemi M, Eskandari-Nasab E, Fazaeli A, Arababi F, Bahrani-Zeidabadi M, et al. Association of-607 C/A polymorphism of IL-18 gene (rs1946518) with breast cancer risk in Zahedan, Southeast Iran. Prague Med Rep. 2012; 113(3):217-22. [PubMed] [Crossref]
10. Giedraitis V, He B, Huang WX, Hillert J. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol. 2001 Jan 1;112(1-2):146-52. [PubMed] [Crossref]
11. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 Feb;69(2):292–302. [PubMed] [Crossref]
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–52. [PubMed] [Crossref]
13. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001 Mar;12(1):53–72. [PubMed] [Crossref]
14. Chen YC, Chen SD, Miao L, Liu ZG, Li W, Zhao ZX, et al. Serum levels of interleukin (IL)-18, IL-23 and IL-17 in Chinese patients with multiple sclerosis. J Neuroimmunol. 2012 Feb 29;243(1-2):56-60. [PubMed] [Crossref]
15. Balasa R, Maier S, Voidazan S, Hutanu A, Bajko Z, Motataianu A, et al. Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response. CNS Neurol Disord Drug Targets. 2017; 16(1):93-101. [PubMed]
16. Keane RW, Dietrich WD, de Rivero Vaccari JP. Inflammasome Proteins As Biomarkers of Multiple Sclerosis. Front Neurol. 2018 Mar 19;9:135. [PubMed] [Crossref]
17. Losy J, Michalowska-Wender G, Wender M. Interleukin 12 and interleukin 10 are affected differentially by treatment of multiple sclerosis with glatiramer acetate (Copaxone). Folia neuropathol. 2002;40(4):173-5. [PubMed].
Received: 24 October 2019
Published online: 01 December 2020
back to Online Journal